An Open-Label, Non-Randomised, Pharmacokinetic, Metabolic Disposition and Safety Study of a 3 Day Continuous Infusion of GR270773 in Healthy Subjects and Subjects With Hepatic Impairment.
Latest Information Update: 06 Sep 2023
At a glance
- Drugs GR 270773 (Primary)
- Indications Sepsis
- Focus Pharmacokinetics
- Sponsors GSK
- 29 Sep 2017 New trial record